Syadyppah; I agree and I'd like to think that the reduction in the bottom line statutory loss bodes well for the future as sales start increasing and the R&D investment and overheads get spread over more volume. Hopefully the Board is cognizant of the need to avoid dilution to existing shareholders and the recent CR gives enough breathing space for the sales pipeline to start allowing the company to self generate; or at least find some more palatable options than dilution. GLTAH
Ann: Appendix 4D - Half Year Report, page-7
Add DRO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.075(5.36%) |
Mkt cap ! $1.122B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.50 | $1.39 | $24.74M | 16.85M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14519 | $1.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 41352 | 1 |
View Market Depth
| Last trade - 15.59pm 29/07/2024 (20 minute delay) ? |
| DRO (ASX) Chart |